Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Shear class gatemore have expressed their interest to sensyne in achieving a nasdaq listing and the below rns confirms that it is something sensyne are looking at
Oxford, U.K. 19 July 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company"), the ethical AI company, announces an update on its strategy which now includes exploring a potential dual-listing on Nasdaq amongst other options. As stated in our financial year end trading update on 27 May 2021, the Company continues to explore strategic opportunities, including making acquisitions, that leverage its organic growth and create additional shareholder value. Any decision to list in the US would complement the Company's primary listing on the AIM market of the London Stock Exchange and Sensyne remains committed to being a UK-headquartered company. Any acquisition or strategic equity partnership would be consistent with Sensyne's commitment to the ethical application of AI to patient data and its established strategic research agreements with the NHS and US health systems.
Has the NASDAQ listing been mentioned anywhere? If not, they will be running out of time to arrange anything before their cash runs out. Cash burn was £25m in YE2021 and that was with revenues of £9m. Considering they only expect to report ~£2m in the current HY ending 31st October, cash burn could very well have increased to around £15m, leaving cash of just £10m, which is falling at > £2m a month. That doesn't leave much room for manoeuvre.
Technically the chart looks vile & I doubt there will be an influx of buyers until the funding position is clarified. If / when SENS reaches breakeven they will be a very interesting proposition, until then the rollercoaster continues.
Personally I don’t think we will see another fund raise on a U.K. market. If there is an ipo on nasdaq then yes. We had plenty of cash in the bank I think 23million at April 2021 and have since signed commercial contracts. There should be more of these coming and if we do end up on the nasdaq then the fund raise will likely be outweighed by the positives of listing in America.
The pharma stocks over there can do silly multiples in a day and I think we are a unique company with a concept that doesn’t take much to grasp so the interest should be widespread if the ipo is marketed properly - I am sure the board are capable.
Unsurprised to see that the price has been butchered since the 1st Oct results. SENS needs to raise more cash, that's why the price is falling.
Have to agree, I also read the DT article having not heard of SENS before and was impressed. I then looked at it via FT Portfolio and was impressed by the fact the company has no sig debt and the forecasts suggest it should go up bigly. I bought 3,000 as a bio-tech-punt and hope to make an SPQR between now and year end.
Extract from Telegraph article for info
"Sensyne has generated £5.1m in sales from its licencing agreement with Excalibur, allowing the company to use MagnifEye in the lateral flow test.
Excalibur would not reveal its sales figures, but said several million of its lateral flow tests have been shipped in the UK and internationally.
Sir Chris said there was a big market opportunity for the new digital test outside of foreign travel testing, such as testing staff in staff large offices.
The company expects to sell tens of thousands of digital tests in the next few months alone, a spokesman for Excalibur said.
“This is a major scientific achievement and, we believe, a world first in developing a regulated software application using AI to enhance the accuracy of lateral flow testing and reporting," said Lord Drayson."
https://www.telegraph.co.uk/business/2021/10/21/digital-lateral-flow-test-produces-covid-certificate-minutes/
Them two thoughts also crossed my mind TT, mayb there’s a few shorters under the radar, doing it just below the 0.5% mark. And yes, I agree with you on the point of takeover being a bit tricky due to the nature of the data we’re dealing with here.
You’re right there Troy, they do offer buys at a price lower than mid point price. This may give the wrong impression to potential investors and may encourage some holders to sell thinking everyone is selling. I tried a dummy buy in the afternoon and was offered a price a tad above the bid price.
I thought perhaps we were being shorted but according to short trackers online there are no positions over 0.5% open.
Could the share price be being held down for a potential takeover? This question crossed my mind but surely confidentiality for patient data would be a very sticky situation if for instance a large pharmaceutical company were to take over. I cannot fathom how this is back at below placing level. The only blessing is the opportunity to average down.
Fully agree ... still surprised to see so many “buys” actually logged as sells... I’ve made 4 trades this week and all identified as “sells” on this forum... could this be putting traders off ? It does appear somewhat misleading...
Great news, the journey to profit making is slow but we can see progress. The current sp price is a real bargain imv, let’s wait and see.
“Test-To-Go System powered by MagnifEye receives European regulatory certification”
Good news ... but will it translate to revenues and hence profit quickly ? Still surprised to see Sensyne trading this low base on positive strategy... just need to see some profitability ...